Literature DB >> 30546960

Virotherapy-recruited PMN-MDSC infiltration of mesothelioma blocks antitumor CTL by IL-10-mediated dendritic cell suppression.

Zhiwu Tan1, Li Liu1, Mei Sum Chiu1, Ka-Wai Cheung1, Chi Wing Yan1, Zhe Yu1, Boon Kiat Lee1, Wan Liu1, Kwan Man2, Zhiwei Chen1,3.   

Abstract

Antitumor cytotoxic T lymphocytes (CTLs) are essential for immune surveillance, yet the blockade of eliciting such CTLs during oncolytic virotherapy remains incompletely understood. Here, we show that oncolysis of mesothelioma by modified vaccinia Tiantan (MVTT) induces damage-associated molecular patterns exposure. Although MVTT leads to regression of established mesothelioma dose-dependently, antitumor CTLs are rarely induced. Mechanistically, MVTT virotherapy generates C-X-C chemokines that recruit CXCR2-expressing polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) into tumor microenvironment, where they suppress dendritic cells (DCs) by producing IL-10 and halt CTL responses. During the virotherapy, however, depletion of PMN-MDSCs but not of monocytic (M)-MDSCs results in the induction of potent antitumor CTLs that not only eradicate established mesothelioma but also prevent the second tumor challenge. Our findings suggest that vaccinia virotherapy may combine strategies that prevent the chemotactic recruitment of PMN-MDSCs, block their suppression on DCs or deplete PMN-MDSCs in order to induce potent CTLs for tumor eradication.

Entities:  

Keywords:  CTLs; MDSCs; Modified vaccinia Tiantan; mesothelioma; virotherapy

Year:  2018        PMID: 30546960      PMCID: PMC6287797          DOI: 10.1080/2162402X.2018.1518672

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  68 in total

1.  Pemetrexed and cisplatin for malignant pleural mesothelioma: a new standard of care?

Authors:  Valerie W Rusch
Journal:  J Clin Oncol       Date:  2003-07-15       Impact factor: 44.544

Review 2.  Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma.

Authors:  Augusto C Ochoa; Arnold H Zea; Claudia Hernandez; Paulo C Rodriguez
Journal:  Clin Cancer Res       Date:  2007-01-15       Impact factor: 12.531

3.  Mutant MHC class II epitopes drive therapeutic immune responses to cancer.

Authors:  Sebastian Kreiter; Mathias Vormehr; Niels van de Roemer; Mustafa Diken; Martin Löwer; Jan Diekmann; Sebastian Boegel; Barbara Schrörs; Fulvia Vascotto; John C Castle; Arbel D Tadmor; Stephen P Schoenberger; Christoph Huber; Özlem Türeci; Ugur Sahin
Journal:  Nature       Date:  2015-04-22       Impact factor: 49.962

4.  Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy.

Authors:  Nicole Glodde; Tobias Bald; Debby van den Boorn-Konijnenberg; Kyohei Nakamura; Jake S O'Donnell; Sabrina Szczepanski; Maria Brandes; Sarah Eickhoff; Indrajit Das; Naveen Shridhar; Daniel Hinze; Meri Rogava; Tetje C van der Sluis; Janne J Ruotsalainen; Evelyn Gaffal; Jennifer Landsberg; Kerstin U Ludwig; Christoph Wilhelm; Monika Riek-Burchardt; Andreas J Müller; Christoffer Gebhardt; Richard A Scolyer; Georgina V Long; Viktor Janzen; Michele W L Teng; Wolfgang Kastenmüller; Massimiliano Mazzone; Mark J Smyth; Thomas Tüting; Michael Hölzel
Journal:  Immunity       Date:  2017-10-17       Impact factor: 31.745

Review 5.  The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity.

Authors:  Je-In Youn; Dmitry I Gabrilovich
Journal:  Eur J Immunol       Date:  2010-11       Impact factor: 5.532

6.  Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment.

Authors:  Alexander M Lesokhin; Tobias M Hohl; Shigehisa Kitano; Czrina Cortez; Daniel Hirschhorn-Cymerman; Francesca Avogadri; Gabrielle A Rizzuto; John J Lazarus; Eric G Pamer; Alan N Houghton; Taha Merghoub; Jedd D Wolchok
Journal:  Cancer Res       Date:  2011-12-15       Impact factor: 12.701

7.  Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy.

Authors:  C Marcela Diaz-Montero; Mohamed Labib Salem; Michael I Nishimura; Elizabeth Garrett-Mayer; David J Cole; Alberto J Montero
Journal:  Cancer Immunol Immunother       Date:  2008-04-30       Impact factor: 6.968

8.  Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy.

Authors:  Jedd D Wolchok; James P Allison; Dmitriy Zamarin; Rikke B Holmgaard; Sumit K Subudhi; Joon Seok Park; Mena Mansour; Peter Palese; Taha Merghoub
Journal:  Sci Transl Med       Date:  2014-03-05       Impact factor: 17.956

Review 9.  Exploiting poly(I:C) to induce cancer cell apoptosis.

Authors:  Francesca Bianchi; Samantha Pretto; Elda Tagliabue; Andrea Balsari; Lucia Sfondrini
Journal:  Cancer Biol Ther       Date:  2017-09-07       Impact factor: 4.742

Review 10.  Oncolytic viruses: a new class of immunotherapy drugs.

Authors:  Howard L Kaufman; Frederick J Kohlhapp; Andrew Zloza
Journal:  Nat Rev Drug Discov       Date:  2015-09       Impact factor: 84.694

View more
  11 in total

Review 1.  Implications of immune cells in oncolytic herpes simplex virotherapy for glioma.

Authors:  Yoshihiro Otani; Ji Young Yoo; Toshihiko Shimizu; Kazuhiko Kurozumi; Isao Date; Balveen Kaur
Journal:  Brain Tumor Pathol       Date:  2022-04-06       Impact factor: 3.298

Review 2.  Targeting Myeloid Cells in Combination Treatments for Glioma and Other Tumors.

Authors:  Andy S Ding; Denis Routkevitch; Christina Jackson; Michael Lim
Journal:  Front Immunol       Date:  2019-07-23       Impact factor: 7.561

Review 3.  Targeting Myeloid-Derived Suppressor Cell, a Promising Strategy to Overcome Resistance to Immune Checkpoint Inhibitors.

Authors:  Aohan Hou; Kaiyu Hou; Qiubo Huang; Yujie Lei; Wanling Chen
Journal:  Front Immunol       Date:  2020-05-15       Impact factor: 7.561

4.  Blocking Migration of Polymorphonuclear Myeloid-Derived Suppressor Cells Inhibits Mouse Melanoma Progression.

Authors:  Christopher Groth; Ludovica Arpinati; Merav E Shaul; Nina Winkler; Klara Diester; Nicolas Gengenbacher; Rebekka Weber; Ihor Arkhypov; Samantha Lasser; Vera Petrova; Hellmut G Augustin; Peter Altevogt; Jochen Utikal; Zvi G Fridlender; Viktor Umansky
Journal:  Cancers (Basel)       Date:  2021-02-10       Impact factor: 6.639

Review 5.  Role of Myeloid Cells in Oncolytic Reovirus-Based Cancer Therapy.

Authors:  Vishnupriyan Kumar; Michael A Giacomantonio; Shashi Gujar
Journal:  Viruses       Date:  2021-04-10       Impact factor: 5.048

Review 6.  Roles of the Exosomes Derived From Myeloid-Derived Suppressor Cells in Tumor Immunity and Cancer Progression.

Authors:  Zhuang Chen; Rui Yuan; Shengyun Hu; Weitang Yuan; Zhenqiang Sun
Journal:  Front Immunol       Date:  2022-01-27       Impact factor: 7.561

7.  Antimesothelioma Immunotherapy by CTLA-4 Blockade Depends on Active PD1-Based TWIST1 Vaccination.

Authors:  Zhiwu Tan; Mei Sum Chiu; Chi Wing Yan; Yik Chun Wong; Haode Huang; Kwan Man; Zhiwei Chen
Journal:  Mol Ther Oncolytics       Date:  2020-02-08       Impact factor: 7.200

8.  Connecting METTL3 and intratumoural CD33+ MDSCs in predicting clinical outcome in cervical cancer.

Authors:  Huan-He Ni; Lin Zhang; He Huang; Shu-Qin Dai; Jiang Li
Journal:  J Transl Med       Date:  2020-10-15       Impact factor: 5.531

9.  Persistent lentivirus infection induces early myeloid suppressor cells expansion to subvert protective memory CD8 T cell response✰,✰✰.

Authors:  Li Liu; Qingqing Lin; Jie Peng; Jun Fang; Zhiwu Tan; Hangying Tang; Kayi Kwan; Kenji Nishiura; Jianguo Liang; Hauyee Kwok; Zhenglong Du; Jiaze Sun; Kang Liu; Kwok-Yung Yuen; Hui Wang; Zhiwei Chen
Journal:  EBioMedicine       Date:  2020-09-24       Impact factor: 8.143

10.  Mechanisms of immune suppression by myeloid-derived suppressor cells: the role of interleukin-10 as a key immunoregulatory cytokine.

Authors:  Mahmoud Mohammad Yaseen; Nizar Mohammad Abuharfeil; Homa Darmani; Ammar Daoud
Journal:  Open Biol       Date:  2020-09-16       Impact factor: 6.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.